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Abstract: Juvenile neuronal ceroid lipofuscinosis (JNCL) is caused by mutations in the CLN3 gene.
Most JNCL patients exhibit a 1.02 kb genomic deletion removing exons 7 and 8 of this gene, which
results in a truncated CLN3 protein carrying an aberrant C-terminus. A genetically accurate mouse
model (Cln3∆ex7/8 mice) for this deletion has been generated. Using cerebellar precursor cell lines
generated from wildtype and Cln3∆ex7/8 mice, we have here analyzed the consequences of the CLN3
deletion on levels of cellular gangliosides, particularly GM3, GM2, GM1a and GD1a. The levels
of GM1a and GD1a were found to be significantly reduced by both biochemical and cytochemical
methods. However, quantitative high-performance liquid chromatography analysis revealed a highly
significant increase in GM3, suggesting a metabolic blockade in the conversion of GM3 to more
complex gangliosides. Quantitative real-time PCR analysis revealed a significant reduction in the
transcripts of the interconverting enzymes, especially of β-1,4-N-acetyl-galactosaminyl transferase
1 (GM2 synthase), which is the enzyme converting GM3 to GM2. Thus, our data suggest that the
complex a-series gangliosides are reduced in Cln3∆ex7/8 mouse cerebellar precursor cells due to
impaired transcription of the genes responsible for their synthesis.
Keywords: Batten disease; neuronal ceroid lipofuscinosis; CLN3; lysosomal storage disorders;
glycosphingolipids; gangliosides
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1. Introduction
Juvenile neuronal ceroid lipofuscinosis (JNCL) is a lysosomal storage disorder caused by
mutations in the CLN3 gene. Most JNCL patients worldwide are homo- or heterozygous for a deletion
that removes exons 7 and 8 together with the bridging intron. A genetically authentic mouse model
for this mutation has been generated, and it has been shown to recapitulate many of the pathogenic
features of human JNCL disease [1–6]. One of the first symptoms in JNCL patients is visual system
impairment that frequently manifests at the age of 5—8 years and leads to blindness due to retinal
degeneration. Within the first decade of life, the patients’ mental and physical capabilities continue
to decline, and epileptic seizures become evident. In addition to the central nervous system, JNCL
patients also exhibit pathologic features in the cardiac and immune systems. Towards the end of the
second decade of life, many patients rapidly deteriorate and become wheelchair bound, with death
usually occurring by the age of 25.
The gene product, CLN3 protein, is a transmembrane protein that is predicted to span the
membrane 6 times, with both N- and C-terminus residing in the cytosol [7,8]. Although the exact
molecular function of the CLN3 protein has not been conclusively verified, it has been linked to various
cellular processes such as autophagy, lysosomal pH, vesicular trafficking and cation homeostasis in
lysosomes [2,4,9,10]. Furthermore, the CLN3 protein has been shown to be associated with cell
proliferation, control of cell cycle and apoptosis. However, it is not clear if these phenotypic features
are directly caused by an impairment of CLN3 protein function or if they represent secondary effects.
Glycosphingolipids (GSLs) are important glycan structures mainly residing at the cell surface,
especially in neuronal cells. GSLs comprise ceramide linked to a varying number of sugar residues.
Gangliosides are a subgroup of GSLs, distinguished by the presence of sialic acid residues, mainly
N-acetylneuraminic acid in humans [11,12]. The biosynthesis pathway and the structures of the
a-series gangliosides with their synthesizing enzymes are shown in Figure 1, and the genes and the
respective enzymes are summarized in Table 1. GM3 is synthesized from lactosylceramide (LacCer) by
the enzyme LacCer sialyltransferase (GM3 synthase) and is the precursor for the a-series gangliosides.
Conversion to GM2 takes place by the action of GM2 synthase (GalNAc transferase). Addition of
a galactose residue to GM2 by galactosyltransferase 2 (GM1 synthase) results in GM1a ganglioside,
which can further be converted into GD1a upon terminal sialylation by a sialyltransferase (GD1a
synthase). GT1a can be synthesized from GD1a by sialylation by GT1a synthase. The same enzymes
are responsible for the synthesis of the b- and c-series gangliosides where the synthesis precursors
arise from GM3 by further sialylation. For a detailed description of the structures of the b- and
c-series, please refer to the review by Daniotti and Iglesias-Bartolomé [13]. Ganglioside synthesis takes
place mainly in the Golgi where glycosyltransferases sequentially add sugar residues to the lipids.
Glycosyltransferase expression is regulated especially at the transcriptional level, but also by formation
of protein complexes comprising several glycosyltransferases [14,15].
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Table 1. Genes and enzymes involved in a-series ganglioside biosynthesis. Only steps beyond LacCer
are shown.
Gene Enzyme Alternative Names Synthesis Step
ST3Gal5 Lactosylceramidesialyltransferase GM3 synthase, Sial-T1 LacCer to GM3
B4GalNT1
GM3
N-acetyl-galactosaminyl
transferase
GM2 synthase, GalNAc-T,
GM3 sialyltransferase GM3 to GM2
B3GalT-4 GM2 galactosyltransferase GM1 synthase, Gal-T2 GM2 to GM1
ST3Gal2 GM1 sialyltransferase GD1a synthase, Sial-T4 GM1 to GD1a
ST3Gal3 GD1a sialyltransferase GT1a synthase, Sial-T5 GD1a to GT1a
In the brain, gangliosides are especially abundant and important for the development and
maintenance of the organ. In particular, a-series gangliosides have been shown to be essential for
neurite outgrowth and cell survival [16,17]. The special role of gangliosides in the central nervous
system is also highlighted by severe human diseases, the gangliosidoses, which result from genetic
defects mainly in the genes involved in the degradation of gangliosides. For example, Tay-Sachs and
Sandhoff diseases, collectively known as the GM2 gangliosidoses, result from impaired degradation
of GM2 ganglioside (For review, see [11]). In addition, secondary accumulation of gangliosides
is observed in sphingolipid storage disorders such as Niemann-Pick Type C disease, in which the
mutated genes are not directly involved in ganglioside metabolism. On the other hand, only few
human diseases have been confirmed to result from genetic defects in the ganglioside biosynthesis
pathways [18–20]. However, diseases that impair sphingolipid metabolism collectively show that
accumulation of specific gangliosides is highly deleterious especially to the central nervous system.
Previous studies have shown that in various NCLs, accumulation of gangliosides or their
precursors may occur. In JNCL cells, accumulation of ceramide has been described [21], and CLN3
protein has been proposed to be involved in galactosylceramide transport [22,23]. Here, we have
analyzed the levels of the more complex gangliosides, with special focus on the a-series, in cerebellar
granule cell precursor lines derived from homozygous Cln3∆ex7/8 mice. We show that specific
alterations in the levels of ganglioside expression are present in this JNCL cell model. In particular, an
accumulation of GM3 ganglioside was observed, whereas levels of the more complex gangliosides,
especially GM1a, were reduced. Furthermore, we detected significantly reduced transcripts of many
of the genes involved in ganglioside biosynthesis and degradation, implicating that in JNCL, there
may be secondary defects that result in altered ganglioside levels.
2. Results
Intracellular accumulation of gangliosides is associated with several lysosomal storage disorders.
In this study, we have quantitatively analyzed the a-series gangliosides in the mouse cerebellar granule
neuronal precursor cell lines generated from wildtype (WT) and homozygous Cln3∆ex7/8 mice [2].
Lipids were extracted from cultured cells and analyzed by high performance liquid chromatography
(HPLC, Figure 2a). Our data revealed a highly significant increase in the ganglioside GM3 in Cln3∆ex7/8
cells (p < 0.001). Furthermore, GM1a and GD1a gangliosides were significantly decreased in Cln3∆ex7/8
cells (p < 0.05 and p < 0.001, respectively), as compared with WT cells. A tendency for increased LacCer
(p = 0.126) and decreased GM2 (p = 0.075) was also observed, but these data were not significant.
We were unable to detect the b-series gangliosides, including GD3, by HPLC analysis, indicating
that the levels of these gangliosides are extremely low in these cells. In agreement with the HPLC
data, immunofluorescence staining of Cln3∆ex7/8 cells showed a reduced amount of GD1a and GM1a,
whereas GM2 was not considerably altered (Figure 2b). Unfortunately, specific, validated antibodies
for GM3 are not commercially available that would allow its detection by immunofluorescence.
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GM1a ganglioside also function as a high-affinity receptor for the choler toxin B subunit (CTX).
Thus, CTX bin ing to Cln3∆ex7/8 cells was use to quantitatively assess GM1a levels. Dot blot analysis
with horseradish peroxidase (HRP) coupled CTX (Figure 3a) revealed a significantly reduced CTX
binding to Cln3∆ex7/8 cell lysates. To study if the eduction of GM1a fraction was global r restricted to
the plasma embrane or intracellul r compartments, flow cytometry analysis of bound CTX-FITC
was performed n igitonin-permeabilized (Figure 3b, plasma membrane d intracellular pools)
and no -permeabiliz cells (Figure 3c, plasma membran pool). A significantly r duced CTX-FITC
binding was det cted in both permeabilized and non-permeabilized Cln3∆ex7/8 cells (Figure 3 ), but
the degree of reduction in non-permeabilized cells was sli htly higher than in cells.
To verify the flow cytometry data, the bind of CTX-FITC to permeabilized or
non-permeabil z d WT a d Cln3∆ex7/8 cells was quantified using a fluorescence plate rea er (Figure 4 ).
A significant difference n CTX intensity between WT and Cln3∆ex7/8 cells was measured both with
and without permeabilization. Again, the degree of reduction in CTX-FITC staining was igh r in
non-permeabilized Cln3∆ex7/8 cells. These data imply that not only the amount but also the relative
distribution of GM1a might be ltered in Cln3∆ex7/8 cells. Fluorescent staining of the cells with
CTX-A488 (Figure 4b) also showed a clear r duction f CTX staining in both permeabilized and
non-permeabilized Cln3∆ex7/8 cells. Taken togeth r, the above data demonstrate that GM1a ganglioside
amount and cellular distribution may be altered in Cln3∆ex7/8 cells.
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(red) cells. The cells were incubated with FITC-coupled CTX to detect surface and intracellular GM1a
pools and analyzed by flow cytometry. Insets in (b,c) represent associated forward and side-scatter plots
to demonstrate size distributions of WT (green) and Cln3∆ex7/8 cells (red). (d) Quantification of the flow
cytometry data from four independent experiments shows a significant reduction of CTX-FITC binding
in both permeabilized and non-permeabilized Cln3∆ex7/8 cells. Significance in (a,d) was assessed using
Student’s t test. * p < 0.05; ** p < 0.01.
Since JNCL is a lysosomal storage disorder with alterations in endosomal/lysosomal system, the
localization of the intracellular CTX in lysosomes was studied using staining with anti-LAMP-1
antibodies in CTX-A488 labeled WT and Cln3∆ex7/8 cells (Figure 5). In both cell lines, the CTX
staining was partially colocalized with the LAMP-1 staining, indicating that although the Cln3∆ex7/8
cells exhibit less CTX staining, the intracellular portion was still mainly localized in the late
endosomal/lysosomal compartments.
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(a) Permeabilized r non-permeabilized WT and Cln3∆ex7/8 cells were incubated with FITC-coupled
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Data are representative for 3 independent experiments.
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degradation. To check if the expression of the enzymes responsible for the synthesis and degradation 
of a-series gangliosides was altered, quantitative real-time PCR experiments were performed (Table 
2). The role of these proteins in ganglioside synthesis/degradation is shown in Section 3. Interestingly, 
the transcript levels of many of the genes encoding enzymes related to ganglioside metabolism were 
either significantly reduced (B4GalNT1, HexA and Neu1) or showed a tendency to be reduced (Glb1). 
Furthermore, cathepsin A/protective protein gene transcript (Ctsa) was significantly reduced, 
whereas the transcript of GM2 activator protein (Gm2a) was not changed. The GM1a sialyltransferase 
gene (St3gal2) transcription was not altered. Importantly, the B3GalT4 gene for the enzyme converting 
GM2 to GM1a was approximately 4.5-fold upregulated, which might represent an attempt of the cells 
to compensate for the reduced GM1a level. These data suggest that in the Cln3Δex7/8 cerebellar 
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Figure 5. GM1a partially colocalizes with lysosomes in both WT and Cln3∆ex7/8 cells. The cells
were stained with CTX-A488 (green) and anti-LAMP1 antibody (red) and imaged using a confocal
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frame in the overlay images on the first and third rows, respectively. Arrows point to examples of
colocalization. The green signal in the overlay image of the Cln3∆ex7/8 cells was enhanced using the
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show representative data from 3 independent experiments.
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The cellular levels of gangliosides may reflect changes either in their biosynthesis or degradation.
To check if the expression of the enzymes responsible for the synthesis and degradation of a-series
gangliosides was altered, quantitative real-time PCR experiments were performed (Table 2). The role
of these proteins in ganglioside synthesis/degradation is shown in Section 3. Interestingly, the
transcript levels of many of the genes encoding enzymes related to ganglioside metabolism were
either significantly reduced (B4GalNT1, HexA and Neu1) or showed a tendency to be reduced (Glb1).
Furthermore, cathepsin A/protective protein gene transcript (Ctsa) was significantly reduced, whereas
the transcript of GM2 activator protein (Gm2a) was not changed. The GM1a sialyltransferase gene
(St3gal2) transcription was not altered. Importantly, the B3GalT4 gene for the enzyme converting GM2
to GM1a was approximately 4.5-fold upregulated, which might represent an attempt of the cells to
compensate for the reduced GM1a level. These data suggest that in the Cln3∆ex7/8 cerebellar precursor
cells, the synthesis and degradation of the a-series gangliosides may be dysregulated due to changes
in the expression of the respective enzymes.
Table 2. Quantitative real-time PCR analysis of the transcript levels of genes involved in ganglioside
synthesis and degradation in mouse cerebellar precursor cells. Data are a summary of three
independent experiments.
Gene
Symbol Enzyme/Protein (Function)
Mean Expression Level± SD p-Value
WT Cln3∆ex7/8
St3gal2 GM1 sialyltransferase 1.0 ± 0.01 1.02 ± 0.01 0.939
B4galNT1 β-1,4-N-acetyl-galactosaminyl transferase 1 1.0 ± 0.03 0.12 ± 0.01 4 × 10−4
Neu1 neuraminidase 1 (GD1a to GM1) 1.0 ± 0.07 0.50 ± 0.04 0.036
Glb1 β-galactosidase (GM1 to GM2) 1.0 ± 0.002 0.57 ± 0.006 0.060
Gm2a GM2 activator protein(assists in degradation of GM1 and GM2) 1.0 ± 0.01 0.78 ± 0.01 0.474
Ctsa cathepsin A(assists in degradation of GD1a and GM1a) 1.0 ± 0.03 0.29 ± 0.04 0.005
Hexa hexosaminidase A (GM2 to GM3) 1.0 ± 0.03 0.20 ± 0.04 0.007
B3galT4 β-1,3-galactosyltransferase,polypeptide 4 (GM2 to GM1) 1.0 ± 0.09 4.46 ± 0.52 0.056
Since the transcript level of GM2 synthase (B4galNT1 gene) was highly significantly reduced,
we tested by Western blot if the protein amount of this enzyme was also altered (Figure 6). Indeed,
we observed a significant reduction of GM2 synthase protein in the Cln3∆ex7/8 (33 ± 9.9%) vs. WT
(100% ± 11%) cells (t test, p = 0.026). This would be consistent with the observed accumulation of GM3
and reduced transcript amount of this enzyme.
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3. Discussion
We have here shown that the levels of the a-series gangliosides are altered in the cerebellar
precursor cell line derived from the genetically accurate Cln3∆ex7/8 mouse model for JNCL.
The most striking features were the reduction of GM1a and GD1a ganglioside levels and
the concomitant increase in GM3. These data are in accordance with our studies using the
Multi-Epitope-Ligand-Cartography [24] in brain slices of homozygous Cln3∆ex7/8 mice, where we
also observed a reduced binding of CTX [25].
Previous studies have provided evidence for altered levels of glycosphingolipids and their
precursors in JNCL cells. The Boustany group has shown that in JNCL patient fibroblasts homozygous
for the major CLN3 deletion mutation, the levels of ceramide, sphingomyelin, galactosylceramide
(GalCer) and glucosylceramide were increased [22]. In studies with JNCL lymphoblasts with the same
CLN3 genotype, similar alterations were detected, together with specific changes in the cellular
localization of the early GSL synthesis intermediates [23]. For example, GalCer was found to
accumulate in the ER and Golgi fractions of the membranes in JNCL cells. This is consistent with
data showing that the WT CLN3 protein exhibits a binding domain for GalCer and might thus be
involved in GalCer transport towards the periphery [22]. Although CLN3 has been suggested to be a
mainly endosomal/lysosomal protein, accurate detection of the localization of the endogenous protein
is a major problem, since the antibodies available are not able to recognize the endogenous protein
and many of them appear to be unspecific [26]. Overexpression studies, however, have revealed a
mainly endosomal/lysosomal localization of CLN3 (see e.g., [7,27,28]). However, ganglioside synthesis
takes place mainly in the early secretory route, and CLN3 trespasses these compartments on its way
towards lysosomes. Thus, it is possible that CLN3 en route interacts with the ganglioside precursors
or even the enzymes responsible for their synthesis. Another possibility is that malfunction of CLN3
protein exhibits an impact on signaling processes, which in turn may result in impaired transcription
of ganglioside synthesis and degradation genes. The molecular mechanisms of how impairment of
CLN3 function affects ganglioside synthesis should be addressed in further studies.
Although the abundance of the early GSL synthesis intermediates in JNCL has been addressed in
several studies (see above), very little data are available on levels of the more complex sphingolipids.
Kang et al. have shown that GM3, GM2 and GM1a are modestly increased in JNCL lymphoblasts,
whereas sphingomyelin was found to be reduced [29]. Our data are partly contradictory to these
findings, as we observed a significant increase in GM3 and a significant decrease in GM1a and GD1a.
However, these differences might be due to the different cell systems used (patient lymphoblasts vs.
mouse cerebellar precursor cell lines) or the methods that were used for GSL detection. Whereas
Kang et al. used thin-layer chromatography [29], our approach is based on the highly sensitive and
quantitative HPLC method. Furthermore, we have normalized our data to total protein amount,
whereas Kang et al. normalized to the ganglioside GT1b of the b-series, which is not expressed in the
cells used in our study [29].
Since JNCL is a lysosomal storage disorder, the impaired lysosomal function might be expected to
affect the lysosomal degradation of GSLs and cause an accumulation of the more complex gangliosides.
However, we only observed an accumulation of GM3, whereas the more complex gangliosides were
reduced. Our qPCR data show a profound dysregulation of the gene network involved in the synthesis
and degradation of a-series gangliosides. Figure 7 summarizes the interconversion pathways of
a-series gangliosides and the genes required for their synthesis (above the arrow) and degradation
(below the arrows) and shows a summary of the qPCR data (genes reduced are shown italics, genes
increased in bold). Especially intriguing is the highly significant reduction of the mRNA and protein
level of the GM2 synthase enzyme (B4GalNT1 gene) which converts GM3 to GM2. In the absence
of this enzyme, one would expect to see an accumulation of GM3 and reduction in the levels of the
more complex a-series gangliosides, which we indeed observed in this study. However, the transcript
levels of several proteins involved in the degradation of gangliosides, such as Neu1, HexA and Ctsa
were also downregulated, whereas the mRNA for GM1a synthase (B3GalT4) was highly upregulated.
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These data point to alterations in the transcriptional regulation of this gene network in the Cln3∆ex7/8
cells. Interestingly, some of the genes involved in GSL degradation have been shown to be part of the
CLEAR gene network (Coordinated Lysosomal Expression and Regulation) that is regulated by the
Transcription Factor EB (TFEB) family [30,31]. Importantly, the CLN3 gene is also part of this network,
and activation of TFEB by oral administration of trehalose in the Cln3∆ex7/8 mouse model has been
shown to ameliorate the neuropathological features [32]. Trehalose also resulted in a high degree of
upregulation of the Ctsa and Hexa genes in JNCL fibroblasts [32]. Thus, further studies should be
carried out to characterize the role of TFEB in the regulation of GSL biosynthetic genes, as it has not
been studied if they are part of the CLEAR network.
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The accumulation of GM3 in Cln3∆ex7/8 cells is most likely explained by the low level of GM2
synthase mRNA and protein. Many of the GSL synthesizing transferase enzymes reside in the Golgi
where they form protein complexes with each other, which is thought to facilitate the direct passing
of the products to the next glycosyltransferase in the biosynthetic pathway (Reviewed in [12,33]).
These enzymes are actively transcriptionally regulated [15]. However, their levels and activity are
also controlled by changes in the cellular localization of the complex, which in turn is influenced
by the stoichiometry of the proteins within the complex. Thus, changes in the expression of one of
the enzymes within the complex may result in altered localization and activity of several enzymes
(Reviewed in [33]). For example, changes in the expression of GM2 synthase may alter the function of
the transferases acting upstream or downstream of it.
Interestingly, although several human genetic disorders of ganglioside degradation are known,
there are only few confirmed examples of gene defects in GSL biosynthesis. GM3 synthase deficiency
leads to a very severe early-onset epilepsy, whereas GM2 synthase deficiency causes a form of
hereditary spastic paraplegia [18,19]. A patient has been reported with an apparent GM2 synthase
deficiency (genetically unconfirmed) with profound GM3 accumulation in brain and liver, associated
with poor motor and physical development accompanied by frequent seizures and death by 3 months
of age [34]. Due to the rarity of human diseases caused by GSL biosynthesis defects, most of the
functional data have been derived from animal models. Knockout of GM2/GD2 synthase results in
high levels of GM3 and GD3 gangliosides and lack of more complex gangliosides [35,36], and these
mice show axonal degeneration and demyelination in the CNS. A double knockout mouse for GM2
and GD3 synthases has been generated, and these mice exhibit only GM3 ganglioside but lack the more
complex gangliosides beyond this point [37]. Interestingly, these mice are prone to fatal audiogenic
seizures and show an early degeneration of the peripheral nerves. In the future, it would be important
to study in the JNCL mouse model if they show a similar pathology and if the pathological features
can be linked to GM3 accumulation.
GM3 is highly abundant during early embryonic development of the brain. In later stages of
development, the amount of GM3 decreases, although GM3 synthase is not differentially expressed
during the embryonic development. It has been shown that the expression of GM2 synthase
significantly increases during fetal development or differentiation of cultured primary neural
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precursors [38]. This results in a reduction in GM3 level and a concomitant increase in the more
complex gangliosides during embryonic brain development.
Studies on animal models have shown that the complex gangliosides are not required for early
embryonic brain development, but they are essential for the maturation and maintenance of the
brain later on, once developed. During post-natal brain maturation, both the levels and degree of
sialylation of gangliosides increase [39,40]. In the adult brain, 75% of the sialic acid content is bound
to gangliosides [41], and the main gangliosides of adult human brain are GM1a, GD1a, GD1b and
GT1b [40] which share the same neutral glycan core but exhibit a varying number of sialic acids [41].
GM3 accumulation and reduction of the more complex gangliosides in JNCL patient brains might
contribute to the pathogenesis of JNCL by impairing brain maturation or maintenance. However,
these changes in GSL levels may also have more direct molecular consequences. GM1a and GD1a
have been suggested to be essential for the myelination process in the brain [42], and GM1a displays
neuroprotective properties by protecting cells from glutamate-induced excitotoxicity [43]. In addition,
GM1a clusters in the cell membrane can activate TrkA nerve growth factor receptors in the absence of
neurotrophins and induce neurite outgrowth via Lyn, Akt and MAPK signaling [44]. Furthermore, in
cerebellar granule cells, GM1a associates with the neuronal cell adhesion molecule TAG-1, which is
required for the correct localization of the potassium channels Kv1.1 and Kv1.2 [45,46]. These findings
suggest that GM1a level in the brain is important for the survival of neurons and that reduced GM1a
might indeed contribute to JNCL pathogenesis.
Recently, considerable attention has been paid to identify pathological features that may be
common to neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s Disease
(PD), but also lysosomal storage disorders with neuropathology. Interestingly, CLN3 has been
suggested to be a physiological regulator of the Alzheimer amyloid precursor protein metabolism [47].
Intriguingly, GM3 was shown to be elevated in AD and Lewy Body dementia, whereas GM1a levels
were found to be decreased in patients with AD, PD and Huntington’s disease (HD) [48–55], suggesting
that altered GM3 and/or GM1a levels might indeed be common to JNCL and some more common
neurodegenerative diseases. In addition, GM1a has been shown to block the cytotoxicity of the
amyloid β peptide and to be protective against other neuronal insults in cell culture models [43,56].
Thus, modulation of ganglioside levels may even exhibit therapeutic potential, as has been shown in
the mouse model for AD, where upregulation of GM1a and GD1a ganglioside levels by elimination
of GD3 synthase reduced the plaque load and resulted in improved memory [57]. Furthermore,
restoration of GM1a level by exogenous administration of GM1a in an HD cell model protected the
cells from apoptosis by activating the phosphatidylinositol 3-kinase/protein kinase B pathway [49].
Exogenous GM1a supplementation has been shown to be relatively safe, apart from a few cases
exhibiting peripheral neuropathy due to presence of anti-GM1a antibodies [58]. Importantly, at least
a small fraction of gangliosides or their precursors can cross both the blood-brain barrier and the
placenta [59]. However, the blood-brain barrier has been shown to be leaky in the JNCL mouse model,
which might facilitate the treatment of JNCL by GM1 substitution [60–62].
In summary, we here describe hitherto undescribed alterations in the amounts of a-series
gangliosides in the cerebellar neuronal precursor cells of the Cln3∆ex7/8 mouse model. Furthermore,
we could show that the transcript amounts of proteins involved in GSL synthesis and degradation
were altered. These data point to aberrations in the transcriptional regulation of the respective genes
as a potential cause for the altered ganglioside amounts. Since GM3 ganglioside accumulation is
per se pathogenic and may contribute to JNCL pathogenesis, it might be possible to revert the GM3
accumulation by affecting the transcription of the genes involved in the regulation of its synthesis,
especially GM2 synthase/B4GalNT1 gene. In future studies, it will be important to characterize the
regulation of the ganglioside synthesis/degradation gene network in more detail and to identify
transcription factors that are responsible for their regulation. In addition, possible alterations in signal
transduction in JNCL cell should be characterized, since signaling processes are highly important for
transcriptional regulation. This knowledge might help to identify novel or even approved drugs that
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target the pathways important for the regulation of ganglioside processing proteins and might thus
provide novel therapeutic alternatives for JNCL.
4. Materials and Methods
4.1. Cell Culture
The experiments were carried out on conditionally immortalized cerebellar (Cb) granule neuronal
precursor cells, derived from P4 Cln3+/+ and homozygous Cln3∆ex7/8 CD1 mice [2]. The Cln3∆ex7/8
mutation present in these cells corresponds to the 1.02 kb deletion found in human JNCL patients.
Culture of these cells was done as described by Fossale et al. [2]. Briefly, the cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 g/L glucose, 110 mg/L sodium pyruvate
and L-glutamate (all from Gibco, Thermo Fisher Scientific, Karlsruhe, Germany) supplemented with
10% fetal bovine serum, 100 µg/mL Penicillin/Streptomycin (Invitrogen, Thermo Fisher Scientific,
Karlsruhe, Germany), 24 mM potassium chloride and 200 µg/ml Geneticin G418 (Invitrogen), at 33 ◦C
under 5% or 8% CO2.
4.2. Antibodies and Toxins; Immunostaining
CTX-FITC and CTX-A488 (Alexa Fluor 488) were from Invitrogen. Anti-GM2 synthase polyclonal
rabbit antibody (Cat. AV45116) was from Sigma-Aldrich (Taufkirchen, Germany), the monoclonal
anti-GAPDH and the polyclonal LAMP-1 antibody from Abcam (Cambridge, UK). Anti-GD1a antibody
(mouse monoclonal MAB5606) was from Millipore (Darmstadt, Germany), anti-GM1 antibody (rabbit,
Cat. 345757) and anti-GM2 antibody (rabbit, Cat. 345759) were from Calbiochem (Darmstadt,
Germany). Either A488- or A546-conjugated donkey anti-rabbit antibody (1:300; Invitrogen) or
A488-conjugated donkey anti-mouse antibody (Invitrogen) were used as secondary antibodies
for immunostaining.
The cells were grown on coverslips for one day, washed once with PBS (phosphate buffered saline)
prior to fixation for 20 min with 4% paraformaldehyde (PFA). After washing with PBS, a quenching
step using 50 µM glycine in PBS was carried out prior to three washing cycles with PBS. Afterwards,
the cells were blocked and permeabilized with 1% BSA and 50 µg/mL digitonin in PBS for 20 min at
room temperature, followed by an incubation with the respective primary antibody for one hour at
room temperature. The cells were washed with PBS three times for five minutes each. Subsequently,
incubation with the fluorochrome-coupled secondary antibody for one hour at room temperature
was performed. After washing, the coverslips were embedded in a mounting medium containing
DAPI (4′,6′-diamidino-2-phenylindole, (Sigma-Aldrich). The fluorescence images have in some cases
as a whole been subjected to contrast or brightness adjustments. No other manipulations have been
performed unless otherwise stated (see Figure 4). Samples were analyzed with a Zeiss LSM710
Confocal Laser Scanning Microscope (Carl Zeiss, Oberkochen, Germany).
4.3. RNA Isolation, cDNA Synthesis and Quantitative Real-Time PCR
For RNA isolation, the cells were suspended in Trizol reagent (Invitrogen), allowed to stand for 5
min at room temperature (RT) before addition of 200 µL chloroform. The samples were mixed and
allowed to rest for 5 min at RT, followed by centrifugation at 12,000 g for 15 min at 4 ◦C. The supernatant
(upper clear phase) was transferred to a new tube, 400 µL isopropanol was added and the tubes were
inverted several times before another rest at RT for 10 min. Subsequently, the samples were centrifuged
at 12,000 g for 10 min at 4 ◦C. The supernatant was discarded, the pellet washed twice with 75% ethanol.
The pellet was air dried before dissolving in 25 µL DEPC (diethylpyrocarbonate, Sigma-Aldrich) water.
Subsequently, the RNA concentrations were measured.
For qPCR, 3 µg of total RNA was reverse-transcribed using the M-MuLV reverse transcriptase
(NEB, Frankfurt am Main, Germany), the M-MuLV buffer and 150 fmol oligo(dT) primers in a total
volume of 45 µL. qRT-PCR was performed using the CFX Connect Real-Time OCR Detection System
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(Bio-Rad, Munich, Germany). Annealing temperature was 60 ◦C for all primers, the sequences of which
are shown in Table 3. Samples were processed as duplicates using 0.2 µL of 10-fold diluted cDNA in a
final volume of 10 µL with iTaqTMUniversal SYBR Green Supermix (Bio-Rad). The ∆Ct-method was
used to quantify the PCR products. The geometric mean of the reference genes RPL13a and B2M was
used for normalization.
Table 3. Oligonucleotides used for quantitative real-time PCR analysis.
Target Gene Primer Name Sequence 5′-3′
St3Gal2 St3Gal2-fwd GACGCCAGCACCTCTGAATGGT
St3Gal2-rev TTGTAGCATCATCCACCACCGC
B4GalNT1 B4GalNT1-fwd GAGATATACCAGGTGAACCTGAG
B4GalNT1-rev CTGCCGGTTGAGTTTATCCA
Neu1 Neu1-fwd CACCCTGAGTTCCGAGTGAACC
Neu1-rev GCTGCTTCTTTCCATCCGTGCT
Glb1 Glb1-fwd CGGTCGACCTCCAATTCTTCGG
Glb1-rev TACTTGACCCTTGGACCACCCA
Gm2a Gm2a-fwd AGCCTCACGATCCAACCTGACC
Gm2a-rev GAGCTCCACCTTCTGAGGAGCA
Ctsa Ctsa-fwd TCACCATCAAGGGTGCCGGA
Ctsa-rev GGATTTCCATGGGTTGCAGCGG
Hexa Hexa-fwd CTACATCCAGACGCTGCTGGAC
Hexa-rev TACTGGCATTTCTTCCCGCCAC
B3GalT4 B3GalT4-fwd GGTTAAAGCCGTCCTCCCACCT
B3GalT4-rev ACCAGTAGTAGGACCGCCAGGA
RPL13a RPL13a-fwd GTTCGGCTGAAGCCTACCAG
RPL13a-rev TTCCGTAACCTCAAGATCTGCT
B2M B2M-fwd CCTGGCTCACACTGAATTCACC
B2M-rev ATGTCTCGATCCCAGTAGACGG
4.4. Western Blot and Dot Blot Analysis
Cells were harvested in lysis buffer (50 mM Tris pH 7.4; 150 mM NaCl; 2 mM EDTA; 1% NP-40)
supplemented with protease inhibitor cocktail (Sigma-Aldrich) and incubated on ice for 30 min.
The cell lysate was cleared by centrifugation, and the protein amount was measured using Bradford
assay. Equal protein amounts were analyzed by 10% SDS polyacrylamide gel electrophoresis and
Western blot. For immunoblotting, the membranes were blocked with 5% non-fat dried milk in TBST
(10 mM Tris, 150 mM NaCl, 0.05% Tween 20) and incubated with the respective primary antibody
overnight at 4 ◦C. After washing, the blots were incubated with HRP-conjugated secondary antibody
in TBST for 1 h at room temperature. After washing, detection of the signal was carried out using
enhanced chemiluminescence.
Proliferating WT and Cln3∆ex7/8 cells were seeded on 6 well plates to a confluence of 20–30%,
grown up to 80% density, and lysed with CellLytic M cell lysis reagent (Sigma-Aldrich) containing
protease inhibitor cocktail. Protein amounts were determined using Bradford assay, and dots with
equal total protein amount were applied on nitrocellulose membranes. The membranes were blocked
with 5% milk powder in PBS. CTX-HRP (Invitrogen, C34780) was used to detect GM1, and the ECL
reaction imaged using Intas ChemoStar (Intas, Göttingen, Germany). Intensity analysis was performed
with ImageJ (National Institutes of Health, Bethesda, MD, USA) after background correction. Thereby,
the mean background value was subtracted from all intensity values, and all values were normalized
to the mean signal intensity value of the WT cells. Statistical significance was determined with
2-way Anova.
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4.5. Flow Cytometry and CTX-FITC Fluorometry
For flow cytometry, 4 × 105 proliferating WT and Cln3∆ex7/8 cells were seeded per well on
6 well plates. After 24 h, the cells were trypsinized and resuspended into ice-cold PBS containing
20 mM HEPES. Subsequently, the cells were either permeabilized with 11 µg/mL digitonin (for
intracellular labeling) or left non-permeabilized (for cell surface labeling), and incubated with 1 µg/mL
CTX-FITC. Labeled cells and unlabeled autofluorescence controls were measured with a BD FACSAria
flow cytometer (10,000 events per sample). WinMDI 2.9 software (J. Trotter, Purdue University,
West Lafayette, IN, USA) was used to compute the geometrical means which were corrected for
autofluorescence and normalized pairwise to the WT sample to adjust for staining and treatment
variations. Paired t-test was used to test for statistical significance.
For fluorometry, 1.0 × 105 proliferating WT and Cln3∆ex7/8 cells per well were seeded in
24 well plates. After 24 h in culture, the cells were washed twice with PBS and fixed with 4%
PFA. Cells were either left non-permeabilized (surface staining) or permeabilized (total staining)
with 20 µg/mL digitonin and labeled with CTX-FITC (1 µg/mL). Fluorescence signal was measured
with a PerkinElmer Victor X3 plate reader (PerkinElmer, Rodgau, Germany), with each treatment
group represented at least as triplicate. Arithmetic mean signals were corrected for autofluorescence.
Unpaired Student’s t-test was used to test for statistical significance.
4.6. High-Performance Liquid Chromatography of Gangliosides
Glycosphingolipids were analyzed essentially as described by Neville et al. [63]. Lipids from
cells were extracted with chloroform:methanol (1:2, v/v) overnight at 4 ◦C. GSLs were then further
purified using solid phase C18 columns (Telos, Kinesis, UK). After elution, GSLs were dried under a
stream of nitrogen and treated with ceramide glycanase (prepared in house from the medicinal leech
Hirudo medicinalis/verbena) to obtain oligosaccharides from GSLs. Liberated glycans were then
fluorescently-labelled with anthranillic acid (2AA). Excess 2AA label was removed using DPA-6S SPE
columns (Supelco, PA, USA). Purified 2AA-labelled oligosaccharides were separated and quantified
by normal phase high-performance liquid chromatography (NP-HPLC) as previously described [63].
The NP-HPLC system consisted of a Waters Alliance 2695 separations module and an in-line Waters
2475 multi λ-fluorescence detector set at Ex λ360 nm and Em λ425 nm. The solid phase used was a
4.6 × 250mm TSK gel-Amide 80 column (Anachem, Luton, UK). A standard 2AA-labelled glucose
homopolymer ladder (Ludger, Oxfordshire, UK) was included to determine the glucose units (GU)
of the HPLC peaks. Individual GSL species were identified by their GU values and quantified by
comparison of integrated peak areas with a known amount of 2AA-labelled BioQuant chitotriose
standard (Ludger). Results were normalized to protein content.
4.7. Statistical Analysis
All experiments were performed at least three times unless otherwise stated. For information on
the statistical tests used, please refer to the figure legends and the sections of materials and methods
describing the respective methods. Values of p < 0.05 were considered significant (*) while values of
p < 0.01 were considered very significant (**) and p < 0.001 extremely significant (***).
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